Stacie Egan, NP
Nurse Practitioner · Ogden, UTNPI 1376062752
Payments from drug & device makers
Across 1,436 payments — averaging $118.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$85K
- Madrigal Pharmaceuticals$66K
- Phathom Pharmaceuticals, Inc.$7K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- Regeneron Healthcare Solutions, Inc.$1K
- plus $6K from 31 others
What the payments were for
- Consulting fees$8,3055%
- Speaking & faculty fees$101,09860%
- Travel & lodging$38,59623%
- Food & beverage$21,22613%
- Education$2780%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 556 | $84,929 |
| Madrigal Pharmaceuticals | 132 | $65,952 |
| Phathom Pharmaceuticals, Inc. | 27 | $7,228 |
| Takeda Pharmaceuticals U.S.A., Inc. | 115 | $2,436 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 155 | $1,645 |
| Regeneron Healthcare Solutions, Inc. | 19 | $1,280 |
| Johnson & Johnson | 36 | $640 |
| Bristol Myers Squibb | 61 | $584 |
| Aimmune Therapeutics, Inc. | 46 | $562 |
| Ardelyx, Inc. | 32 | $546 |
| QOL Medical, LLC | 34 | $518 |
| Pfizer | 65 | $474 |
| Redhill Biopharma Inc. | 35 | $414 |
| Nestle Healthcare Nutrition Inc. | 27 | $367 |
| Sanofi | 19 | $365 |
| Novo Nordisk | 9 | $219 |
| Merck | 10 | $186 |
| Lilly USA, LLC | 7 | $175 |
| Braintree Laboratories, Inc. | 7 | $132 |
| Celltrion USA Inc. | 6 | $130 |
| Gilead | 5 | $84 |
| Ipsen Biopharmaceuticals, Inc | 4 | $82 |
| Ferring Pharmaceuticals Inc. | 4 | $78 |
| Fresenius Kabi USA, LLC | 4 | $70 |
| Boehringer Ingelheim | 3 | $68 |
| Intercept Pharmaceuticals, Inc. | 3 | $49 |
| Daiichi Sankyo Inc. | 2 | $44 |
| Sandoz | 2 | $40 |
| Boston Scientific | 2 | $35 |
| Amgen | 1 | $31 |
| Ironwood Pharmaceuticals, Inc | 2 | $28 |
| Mylan Institutional Inc. | 1 | $25 |
| Digestive Care, Inc. | 1 | $22 |
| Hologic Sales And Service, LLC | 1 | $19 |
| Lucid Diagnostics Inc. | 1 | $17 |
| GSK | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$169,503 in reported general payments places this provider in the 95th percentile of 979 nurse practitioner providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 79 | $587,398 |
| ZenpepLipase/Protease/Amylase | 56 | $502,437 |
| RezdiffraResmetirom | 13 | $52,374 |
| LinzessLinaclotide | 73 | $51,886 |
| TrulancePlecanatide | 24 | $19,980 |
| Mesalamine | 25 | $10,432 |
| Esomeprazole Magnesium | 149 | $9,121 |
| Budesonide DrBudesonide | 50 | $9,052 |
| Omeprazole | 319 | $7,494 |
| Budesonide EcBudesonide | 27 | $6,697 |
| Dexlansoprazole DrDexlansoprazole | 22 | $6,587 |
| Lubiprostone | 26 | $3,191 |
| Vancomycin Hcl | 18 | $3,163 |
| Lansoprazole | 66 | $2,977 |
| Colestipol Hcl | 21 | $2,814 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $84,929 | $639,284152 claims |
| Aimmune Therapeutics, Inc.Zenpep | $562 | $502,43756 claims |
| Madrigal PharmaceuticalsRezdiffra | $65,952 | $52,37413 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $1,645 | $19,98024 claims |
| SandozLansoprazole | $40 | $2,97766 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 979 nurse practitioner providers in Utah.
Other nurse practitioner in Ogden
- Lynn LarsenOgden$16K
- Marinda PaskettOgden$13K
- Ryan WestbroekOgden$12K
- Aaron AdamsOgden$12K
- Austin BennionOgden$9K
- Raymond MillerOgden$6K
- Nancy ShinaOgden$4K
- Elizabeth ThompsonOgden$4K
- David GambleAmerican Fork$836K
- Julia BattenSalt Lake City$223K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.